We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Level up your trading with our powerful tools and real-time insights all in one place.
The current CRRTF market cap is 8.73M. The company's latest EPS is CAD -0.1022 and P/E is -5.48.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Revenue | 22.34M | 15.64M | 16.77M | 23.53M | 17.52M |
| Operating Income | 4.97M | -363k | -711k | 472k | -1.94M |
| Net Income | 1.86M | 37k | -1.11M | 862k | -1.99M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Total Assets | 26.84M | 26.83M | 28.92M | 28.48M | 24.6M |
| Total Liabilities | 5.73M | 5.7M | 8.4M | 7.39M | 5.78M |
| Total Equity | 21.11M | 21.13M | 20.53M | 21.1M | 18.82M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| CAD ($) | CAD ($) | CAD ($) | CAD ($) | CAD ($) | |
| Operating | 5.31M | 5.61M | -1.6M | -1.02M | 2.08M |
| Investing | -215k | -59k | -846k | -290k | -133k |
| Financing | -4.39M | -476k | -500k | -1.85M | -782k |
| Market Cap | 8.73M |
| Price to Earnings Ratio | -5.48 |
| Price to Sales Ratio | 0.62 |
| Price to Cash Ratio | 1.16 |
| Price to Book Ratio | 0.58 |
| Dividend Yield | - |
| Shares Outstanding | 19.44M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | 60.36% |
| 52 Week High | 0.45671 |
| 52 Week Low | 0.021 |
| Spread (Intraday) | 0.28 (56.64%) |
| Company Name | Crescita Therapeutics Inc (PK) |
| Address |
6733 mississauga road mississauga, ontario L5N 6J5 |
| Website | https://www.crescitatherapeutics.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
